Status:
COMPLETED
Effects of Docosahexaenoic Acid (DHA) on Cardiovascular Disease on Diabetic Patients
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Type 2 Diabetes
Eligibility:
FEMALE
55-75 years
Phase:
NA
Brief Summary
Aim: to determine the effects of DHA supplementation: * on the platelet function through their aggregation and the pathway of arachidonic acid metabolism * on redox status on cells and plasma * on in...
Eligibility Criteria
Inclusion
- woman
- Type 2 diabetes
- Menopausal or aged between 55 and 75 years old
- Recent HbA1c between 6.5-10%
- Oral anti-diabetic drugs or insulin therapy
- Hypertension or antihypertensive drug
Exclusion
- Tobacco
- Excessive drinking
- Post-menopausal hormonal treatment
- Treatment by acetylsalicylic acid, clopidogrel, gliclazide, ticlopidine, NSAID
- Secondary cardiovascular prevention
- antioxidant using
- Fish intake \>2 times a week
- Anemia \<10g/L
- Thrombopenia \<110g/L
- Creatinine clearance \<30 ml/min and/or proteinuria \>1g/L
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01150292
Start Date
May 1 2010
End Date
February 1 2013
Last Update
May 28 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon
Bron, France
2
Centre de Recherche en Nutrition Humaine (CRNH) Rhône-Alpes
Pierre-Bénite, France